Group 1: Pharmaceutical Business Performance - In the first half of 2025, the pharmaceutical business group achieved a main business revenue of CNY 4.751 billion, a year-on-year increase of 10.8% [2] - Sales revenue of Yunnan Baiyao aerosol exceeded CNY 1.453 billion, with a significant year-on-year growth of over 20.9% [2] - Other traditional Chinese medicine products showed remarkable growth, with sales of Canling Jianpi Granules exceeding CNY 100 million and Pudilan Anti-inflammatory Tablets nearing CNY 100 million [2] Group 2: Online Sales and Marketing - The pharmaceutical business group expanded its online market, with O2O sales increasing by over 20% year-on-year [3] - During the 2025 "618" shopping festival, the company’s main products ranked significantly higher on the regular medicine list [3] - E-commerce platforms attracted 48.45 million visitors, resulting in 3.54 million consumers and generating a GMV of CNY 254 million [3] Group 3: Health Products Strategy - The health products group aims to become a leader in high-quality health lifestyle products, focusing on oral care and hair care [4] - Continuous enhancement of oral product advantages and rapid scaling of hair care business are key objectives for the second half of the year [4] Group 4: Nuclear Medicine Development - The INR101 diagnostic nuclear medicine project has initiated Phase III clinical trials, with 32 research centers established and 60 subjects enrolled [5] - The INR102 therapeutic nuclear medicine project has received clinical trial approval, with 12 patients enrolled in Phase I trials [5] Group 5: Traditional Chinese Medicine Resource Development - The Chinese medicine resource group focuses on Yunnan's local medicinal materials, achieving significant results through collaborative efforts [6] - The establishment of 14 seed source bases and the completion of 90% of the annual target for quality seed promotion [6] - The digital cloud medicine platform achieved a transaction volume exceeding CNY 1 billion, with 18,000 registered farmers [6] Group 6: Future Directions for Provincial Pharmaceutical Company - The provincial pharmaceutical company plans to enhance market share in existing hospitals and distribution channels while exploring new growth areas [8] - Strategies include optimizing supply chain management and improving accounts receivable and inventory structure [8]